Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2025
0mins
Source: Yahoo Finance
FDA Approval: The U.S. FDA has expanded the label for Telix Pharmaceuticals' Illuccix® to include patient selection for radioligand therapy in prostate cancer before chemotherapy, potentially increasing its clinical use by 20,000 scans annually.
Clinical Impact: This approval allows for earlier and more personalized treatment decisions for prostate cancer patients, enhancing the standard of care with PSMA-PET imaging for better identification of candidates for targeted therapy.
Analyst Views on TLX
About TLX
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
